Skip to main content

Table 3 Cost effectiveness of UMEC/VI compared with tiotropium

From: Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

Scenario

Incremental QALYs

Incremental costs

ICER

Base case

0.18

£372.29

£2087.60

UMEC/VI price = tiotropium + 10 %

0.18

£687.81

£3856.87

UMEC/VI price = tiotropium + indacaterol

0.18

£3128.15

£17,540.98

Scenario A

0.01

−£0.89

Dominant

Scenario B

0.04

£22.69

£567.04

Scenario C

0.01

−£3.67

Dominant

  1. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, UMEC/VI umeclidinium bromide-vilanterol